These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1333367)

  • 1. Relationships between various uses of antineoplastic drug-interaction terms.
    Wampler GL; Carter WH; Campbell ED; Keefe PA
    Cancer Chemother Pharmacol; 1992; 31(2):111-7. PubMed ID: 1333367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
    Chou TC; Motzer RJ; Tong Y; Bosl GJ
    J Natl Cancer Inst; 1994 Oct; 86(20):1517-24. PubMed ID: 7932806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
    Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
    Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different interaction of cisplatin and etoposide on in vivo and in vitro tumor systems.
    Soranzo C; Pratesi G; Zunino F
    Anticancer Drugs; 1990 Oct; 1(1):23-8. PubMed ID: 2131031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combination effects of etoposide with other antitumor drugs in vitro and in vivo].
    Nishikawa K; Kusama K; Ekimoto H; Takahashi K
    Gan To Kagaku Ryoho; 1989 Dec; 16(12):3739-45. PubMed ID: 2596858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of in vitro synergy between etoposide and cis-diamminedichloroplatinum(II).
    Tsai CM; Gazdar AF; Venzon DJ; Steinberg SM; Dedrick RL; Mulshine JL; Kramer BS
    Cancer Res; 1989 May; 49(9):2390-7. PubMed ID: 2706626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antileukemic activity and development of resistance to cisplatin (CPT) and platinum (IV)-nitroxyl complex VS118].
    Goncharova SA; Raevskaia TA; Iakushchenko TN; Blokhina SV; Konovalova NP; Sen' VD
    Vopr Onkol; 2011; 57(3):355-8. PubMed ID: 21882607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines.
    Zangemeister-Wittke U; Schenker T; Luedke GH; Stahel RA
    Br J Cancer; 1998 Oct; 78(8):1035-42. PubMed ID: 9792147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
    Chan DC; Gera L; Stewart JM; Helfrich B; Zhao TL; Feng WY; Chan KK; Covey JM; Bunn PA
    Clin Cancer Res; 2002 May; 8(5):1280-7. PubMed ID: 12006549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
    Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
    Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines.
    Kalemkerian GP; Ou X
    Cancer Chemother Pharmacol; 1999; 43(2):145-50. PubMed ID: 9923820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Combination Synergy in Worm-like Polymeric Micelles Improves Treatment Outcome for Small Cell and Non-Small Cell Lung Cancer.
    Wan X; Min Y; Bludau H; Keith A; Sheiko SS; Jordan R; Wang AZ; Sokolsky-Papkov M; Kabanov AV
    ACS Nano; 2018 Mar; 12(3):2426-2439. PubMed ID: 29533606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of synergism by a novel three-dimensional model for the combined action of cisplatin and etoposide on the growth of a human small-cell lung-cancer cell line, SBC-3.
    Kanzawa F; Nishio K; Fukuoka K; Fukuda M; Kunimoto T; Saijo N
    Int J Cancer; 1997 May; 71(3):311-9. PubMed ID: 9139860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-alpha and interferon-gamma combined with chemotherapy: in vitro sensitivity studies in non-small cell lung cancer cell lines.
    Hand A; Pelin K; Halme M; Ekman A; Mattson M; Vallas M; Mattson K; Linnainmaa K; Husgafvel-Pursiainen K
    Anticancer Drugs; 1993 Jun; 4(3):365-8. PubMed ID: 8395259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxorubicin sensitivity pattern in a panel of small-cell lung-cancer cell lines: correlation to etoposide and vincristine sensitivity and inverse correlation to carmustine sensitivity.
    Jensen PB; Roed H; Sehested M; Demant EJ; Vindeløv L; Christensen IJ; Hansen HH
    Cancer Chemother Pharmacol; 1992; 31(1):46-52. PubMed ID: 1360876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.
    Kanzawa F; Koizumi F; Koh Y; Nakamura T; Tatsumi Y; Fukumoto H; Saijo N; Yoshioka T; Nishio K
    Clin Cancer Res; 2001 Jan; 7(1):202-9. PubMed ID: 11205910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic synergism of tiazofurin and selected antitumor drugs against sensitive and resistant P388 leukemia in mice.
    Harrison SD; O'Dwyer PJ; Trader MW
    Cancer Res; 1986 Jul; 46(7):3396-400. PubMed ID: 3708573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines.
    Groen HJ; Sleijfer S; Meijer C; Kampinga HH; Konings AW; De Vries EG; Mulder NH
    Br J Cancer; 1995 Dec; 72(6):1406-11. PubMed ID: 8519652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo effects of cisplatin and etoposide in combination on small cell lung cancer cell lines.
    Kondo H; Kanzawa F; Nishio K; Saito S; Saijo N
    Jpn J Cancer Res; 1994 Oct; 85(10):1050-6. PubMed ID: 7961107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun terminal kinase) activation.
    Yoshida S; Kawaguchi H; Sato S; Ueda R; Furukawa K
    Jpn J Cancer Res; 2002 Jul; 93(7):816-24. PubMed ID: 12149148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.